Back to top
more

Puma Biotechnology (PBYI)

(Delayed Data from NSDQ)

$5.07 USD

5.07
229,932

+0.05 (1.00%)

Updated Apr 30, 2024 04:00 PM ET

After-Market: $5.05 -0.02 (-0.39%) 6:14 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (79 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4

Rocket Pharmaceuticals' (RCKT) fourth-quarter earnings beat estimates. Devoid of marketed drugs, the company did not report any revenues during the quarter.

Puma Biotechnology (PBYI) to Report Q4 Earnings: What's in Store?

On Puma Biotechnology's (PBYI) fourth-quarter 2023 earnings call, investors' focus is likely to be on the sales performance of its sole marketed cancer drug, Nerlynx.

Theravance's (TBPH) Q4 Earnings & Revenues Surpass Estimates

Theravance's (TBPH) fourth-quarter earnings and revenues beat estimates. The company achieves profitability on an adjusted basis during the same time. Stock rises.

Fate Therapeutics (FATE) Q4 Earnings Beat, Revenues Fall Y/Y

Fate Therapeutics (FATE) reports encouraging fourth-quarter results as loss narrows year over year due to lower operating expenses.

Bausch (BHC) Q4 Earnings and Revenues Top Estimates

Bausch (BHC) fourth-quarter earnings and sales beat their respective estimates. The guidance for 2024 looks encouraging.

BioMarin (BMRN) Posts Q4 Earnings Beat, Upbeat Voxzogo Sales

BioMarin (BMRN) reports encouraging fourth-quarter results, with earnings and sales beating estimates. The rapid uptake of Voxzogo boosts revenues.

Intellia (NTLA) Beats on Q4 Earnings, Provides Pipeline Update

Intellia's (NTLA) earnings beat estimates in the fourth quarter while the company reports negative revenues. Management provides developmental and regulatory updates on its key pipeline candidates.

Karuna's (KRTX) Q4 Loss Widens, Focus on Bristol Myers Buyout

Karuna's (KRTX) fourth-quarter 2023 earnings and revenues miss estimates. The company is set to be acquired by Bristol Myers.

Intra-Cellular (ITCI) Q4 Loss Narrower Than Expected, Sales Miss

Intra-Cellular (ITCI) reports mixed fourth-quarter 2023 results despite Caplyta sales rising year over year on the back of increasing prescription trends.

Moderna (MRNA) Beats on Q4 Earnings & Sales, Reiterates View

Moderna (MRNA) beats expectations for earnings and sales. Management reiterates guidance to record around $4 billion from product sales in 2024.

United Therapeutics (UTHR) Q4 Earnings & Sales Beat Estimates

United Therapeutics' (UTHR) fourth-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.

Repligen (RGEN) Stock Down on Q4 Earnings Miss, Revenues Fall Y/Y

Repligen's (RGEN) fourth-quarter 2023 earnings miss estimates and decline year over year. Stock declines.

CRISPR (CRSP) Q4 Earnings Top on Collaboration Revenues, Stock Up

CRISPR (CRSP) gains on encouraging fourth-quarter 2023 results, beating both earnings and revenue estimates on the back of collaboration revenues received from Vertex.

Puma Biotech (PBYI) Is Up 23.01% in One Week: What You Should Know

Does Puma Biotech (PBYI) have what it takes to be a top stock pick for momentum investors? Let's find out.

AbbVie (ABBV) Announces Appointment of New CEO Robert Michael

Robert Michael is set to succeed Richard A. Gonzalez as AbbVie's (ABBV) CEO, effective Jul 1, 2024.

Axsome (AXSM) Stock Falls Despite Q4 Earnings & Revenue Beat

Axsome (AXSM) stock declines despite narrower-than-expected loss in the fourth quarter of 2023. Its sales also beat estimates.

Bristol Myers' (BMY) Krazati sNDA for CRC Gets Priority Review

Bristol Myers (BMY) announces FDA's acceptance of the sNDA seeking approval for the Krazati/Erbitux combo therapy to treat CRC patients. A final decision is expected on Jun 21, 2024.

Bayer (BAYRY) Intends to Slash Dividends Amid Challenges

Bayer (BAYRY) announced plans to cut dividends to pay out only the legally required minimum for three years in the wake of high debt and increasing legal costs.

Pfizer's (PFE) Ulcerative Colitis Pill Velsipity Gets EU Nod

The approval for Pfizer's (PFE) Velsipity (etrasimod) is based on data from two pivotal phase III studies, ELEVATE UC 52 and ELEVATE 12.

Roche's (RHHBY) Xolair Gets Approval for Food Allergies

Roche (RHHBY) obtains FDA approval for Xolair for the treatment of children and adults with one or more food allergies.

Iovance (IOVA) Stock Rises on FDA Nod for Melanoma Drug Amtagvi

The FDA grants accelerated approval to Iovance's (IOVA) Amtagvi (lifileucel) for treating advanced melanoma after anti-PD-1 and targeted therapy. Stock rises.

TScan Therapeutics, Inc. (TCRX) Stock Jumps 18.1%: Will It Continue to Soar?

TScan Therapeutics, Inc. (TCRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Corcept (CORT) Q4 Earnings Beat Estimates, Korlym Sales Grow

Corcept (CORT) beats on both earnings and sales in the fourth quarter. The company also reiterates its previously provided guidance for 2024.

Agios (AGIO) Q4 Earnings & Revenues Fall Short of Estimates

Agios' (AGIO) earnings and revenues miss estimates in the fourth quarter of 2023. Revenues from its sole marketed drug, Pyrukynd, rise year over year.

Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat

Ultragenyx (RARE) reports better-than-expected fourth-quarter 2023 results, beating both earnings and revenue estimates, driven by strong sales trends of Crysvita and Dojolvi.